The human proto-oncogene c-erbB-2 codes for a putative transmembrane receptor protein similar in structure to the epidermal growth factor (EGF) receptor, and has been mapped to band q21 of chromosome 17 . It is the human analogue of the transforming gene neu, originally found in rat neuroblastoma cell lines derived from tumours induced by ethylnitrosourea (Bargmann et al., 1985; Yamamoto et al., 1986) . The gene has been shown to be conserved in vertebrates, suggesting that it fulfils an indispensable function (Semba et al., 1985) . It codes for a 185-190 kilodalton glycoprotein and has the tyrosine kinase activity characteristic of several known growth factor receptors Schechter et al., 1984) .
The similarity of the c-erbB-2 protein to the EGF receptor, which is known to be overexpressed on the surface of cells of epidermoid carcinomas, prompted a search for amplification of this gene in human carcinoma. Varying degrees of amplification have been found in a range of human adenocarcinomas, most notably breast carcinoma (Semba et al., 1985; Yokota et al., 1986; van de Vijver et al., 1987; Zhou et al., 1987) . A causal relation was suggested by Di Fiore et al. (1987) who showed that overexpression of the gene product in NIH/3T3 cells in culture induced malignant transformation at levels of gene product comparable to those found in human breast tumour cells. The finding in neuroblastomas of a clear correlation between the extent of amplification of an oncogene (n-myc) and aggressiveness of disease (Seeger et al., 1985) has stimulated further studies. Slamon and colleagues (1987) found c-erbB-2 amplification to be a significant predictor of overall survival and time to relapse. They demonstrated that amplification had prognostic importance greater than most currently employed variables in those patients who were lymph node positive.
Concurrent with this work has been the production of antibodies 20N and 21N raised to predicted amino acid sequences of the gene product . Gene amplification has been shown to be closely associated with immunohistochemical assessment of the gene product in both frozen and paraffin embedded material (Venter et al., 1987; van de Vijver, 1988) . A recent study by Gusterson et al. (1988) indicates that the best association is with membrane staining by the polyclonal antibody 21N raised to the predicted amino acid sequence from residues 1243-1255 of the open reading frame of c-erbB-2. This immunohistochemical technique allows relatively simple retrospective analysis of archival material. Such a study is described below, evaluating tumours from patients on whom detailed follow-up data are available.
Materials and methods

Patients
Primary mammary carcinomas from 195 female patients were examined (age range 30-80 years; median 54 years). The patients presented with operable primary breast carcinoma between 1976 and 1978 and follow-up data to the time of the study, obtained by careful review of clinical records, were available on all. The diagnosis and date of recurrence were determined in a standard manner according to the criteria of Hayward et al. (1978) . The cases were selected to include patients both with and without pathologically involved nodes at presentation. The material within each group was further subdivided to include patients who had subsequently recurred and those who had not. All patients were treated by modified radical mastectomy. A small number had received adjuvant melphalan chemotherapy. This regimen was subsequently found not to affect the clinical outcome (Rubens et al., 1983) , so in our analysis these cases were not treated separately. It (King et al., 1977) . At presentation the histological type of all tumours was determined and all infiltrating ductal carcinomas were graded according to the criteria of Bloom and Richardson (1957) .
Immunohistochemistry
For the present study 5 um sections of tumour were cut from formalin-fixed paraffin-embedded material, in most cases from one representative block but in some cases tissue from more than one block was analysed. The sections were dewaxed and placed in 0.1% hydrogen peroxide in methanol 0.01 M PBS pH 7.2 (5: 3) to block endogenous peroxidase activity. After washing in tap water followed by PBS, the sections were incubated with foetal calf serum/PBS (1:4) for 10 min (in order to reduce non-specific staining with primary antibody). Sections were then coated with 21N polyclonal primary antibody at dilutions of 1/400 and 1/1000 in PBS and left at room temperature overnight (preliminary work was carried out using affinity purified 21N antibody, but for this complete study whole rabbit serum was used at the dilutions indicated). Next day sections were washed in PBS for 10 min and incubated with secondary antiserum (biotinylated swine anti-rabbit immunoglobulin (Dakopatts)) at 1/500 dilution in PBS containing 15% foetal calf serum and 3% human serum for 30 min and then rewashed in PBS. Treatment with avidin-biotin peroxidase complex (Dakopatts ABC complex) followed for 30 min. Peroxidase activity was demonstrated using diamino-benzidine solution (Sigma) and the nuclei were counterstained with haematoxylin.
The specificity of the reaction was confirmed by abolition of staining following pre-incubation of antibody with the immunising peptide (1 mg ml-1). Negative controls in which PBS replaced the primary antiserum were run with each batch of stains. A previously identified strongly staining tumour was used as a positive control. Inter and intra assay consistency was maintained by running these positive and negative controls with each batch of staining. Any assay in which either control was unsatisfactory was repeated. In a small number of positive tumours dilution studies were performed in order to analyse the effect of varying concentrations of primary antibody on the distribution of staining.
Staining assessment A variety of staining patterns was observed in the tumour cells; both cytoplasmic and membrane staining were seen. In all tumours which showed positive staining the majority of cells exhibited the same pattern. Staining intensity of both the cytoplasm and membranes was assessed separately for in situ (when present) and infiltrating components according to a graded scoring system -0 (no staining), 1 (weak), 2 (moderate) and 3 (strong). To determine which of these features was of greatest clinical relevance, different combinations were assessed for each patient: firstly a composite score giving equal weight to both cytoplasmic and membrane staining; secondly a score noting the staining of the infiltrating tumour only; and thirdly a score reflecting membrane staining only. Analysis using these different scores gave similar results. Since it has been shown that membrane staining has the best association with gene amplification, the results below refer to membrane staining only. The use of 2 dilutions of antibody assisted in the assessment of staining intensity. In the weak staining tumours membrane staining was present but extremely faint at 1/1000 dilution, whilst the strong stainers were similarly positive at both dilutions. All cases were reviewed by two people, the few occasions of disagreement were resolved by consultation. In the cases where membrane stain was noted, its presence was confirmed by repeat assay. Furthermore the intensity of staining in the repeat assay was always similar to that in the original.
Statistics
The chi-squared (x2) test for trend was used to evaluate the statistical significance of the relationship between staining and other established prognostic variables. The relationship between staining and clinical outcome was assessed using actuarial survival curves and groups compared by the logrank test (Peto et al., 1977) . Cox regression analysis was used to compare survival experience after adjusting for other prognostic variables, using the programme BMDP2L (Dixon, 1985 In a few cases patchy weak cytoplasmic staining was noted in benign mammary tissue, including normal lobules, areas of sclerosing adenosis and, in particular, apocrine metaplasia.
Seventeen tumours (9%) showed strong or very strong membrane staining (Figure 3) . On the basis of previous studies (Venter et al., 1987; Gusterson et al., 1988; van de Vijver et al., 1988 ) such staining was interpreted as being consistent with considerable c-erbB-2 amplification. Fourteen of these tumours were infiltrating ductal (Figure 4) Comparison of staining scores in the in situ and infiltrating components of the 118 tumours showing both patterns of growth revealed no significant difference.
The staining in the metastatic lesions (11 cutaneous, 2 lymph node, 2 contralateral breast) was compared with the respective primary tumours. Within the limits of sensitivity of the technique, staining in the metastases did not differ significantly from that in the primaries. Three of the pairs were strongly stained; 12 stained weakly or not at all.
Five patients subsequently developed tumours in the contralateral breast which were considered, on histological grounds, to represent second primary growths. All were observed to show similar staining reactions to the initial primary carcinoma. (1987) and 17% in that of Zhou et al. (1987) . Antibodies have now been raised to two synthetic peptides from the predicted sequence of the human c-erbB-2 protein . Antibody 20N was raised against residues 1215-1225 of the c-erbB-2 open reading frame and was used inimmunohistochemical studies on frozen sections of mammary carcinomas (Venter et al., 1987) . The antibody 21N was raised against amino acids 1243-1255, the predicted cterminus of the c-erbB-2 protein and this, together with 20N, was used by Gusterson et al. (1988) in an immunohistochemical study of c-erbB-2 in routinely fixed sections of human breast cancer. The immunohistochemical studies were accompanied by parallel assessment of the c-erbB-2 gene using Southern blotting. It was found that c-erbB-2 amplification was present in tumours which showed strong membrane staining using the immunohistochemical technique.
The main advantage of the immunohistochemical approach is that it allows rapid assessment of archival material from patients with known follow-up. In addition, tissue localisation of the gene product may be analysed. The technique does, however, suffer from certain disadvantages. Although a close association has been observed between gene amplification, as determined by Southern blotting, and overexpression of the gene product, as determined immunohistochemically (Gusterson et al., 1988; Venter et al., 1987) the agreement is not perfect. In addition, one study with 21N and related antibodies revealed that, while recognising the c-erbB-2 protein and not the structurally related EGF receptor, 21N immunoprecipitates several additional bands of varying size which have yet to be identified . Despite this apparent lack of specificity 21N staining does, however, relate more closely to the gene amplification than related antibodies (Gusterson et al., 1988) . Van (1987) did not find a statistically significant association, in agreement with the present study. The combination of a large number of survivors and a small proportion of tumours showing staining means, however, that we cannot rule out the possibility of an association between staining and survival.
It is generally agreed that c-erbB-2 amplification is not restricted to any particular histological tumour type (Escot et al., 1986; Gusterson et al., 1988; van de Vijver et al., 1987; Zhou et al., 1987) and does not correlate with oestrogen receptor status (Gusterson et al., 1988; Slamon et al., 1987; Zhou et al., 1987) . A correlation with lymph node status has been suggested by some (Slamon et al., 1987; Zhou et al., 1987) but not by others (Gusterson et al., 1988) . Previous studies have not shown an association between amplification and grade III tumours (van de Vijver et al., 1987; Zhou et al., 1987) . Such conflicting results may be attributable partly to small samples, differences in study design and the use of different techniques to reveal c-erbB-2 gene and its product.
In the present study similar staining patterns have been demonstrated in the in situ and infiltrating components of mammary carcinoma. This strongly suggests an early role for c-erbB-2 amplification in the pathogenesis of breast cancer. It is arguable whether in a multi-step process an early event such as this is likely to be involved in the subsequent steps of tumour dissemination. The observation of comparable staining in primary and secondary tumours in this study and that of Gusterson et al. (1988) also argues against a direct role for c-erbB-2 amplification in the process of tumour dissemination.
Further studies are required to resolve the prognostic role BJC-E of c-erbB-2. It is possible that c-erbB-2 amplification is merely a marker for pathogenic amplification of a neighbouring gene. A number of genes have been implicated in the pathogenesis of breast cancer (Chan & McGee, 1987; Escot et al., 1986; van de Vijver et al., 1987) and it is likely that others will be found. It may well be too much to expect any one gene to relate closely to behaviour whilst all may contribute to the same phenotype. It has been suggested (Bishop, 1987) that there is no evidence at present to assign inevitable roles in tumorigenesis to individual genes.
